Filling the drug discovery gap: is high content screening the missing link?
In recent years, questions about the sustainability of the current drug discovery process have triggered a revival of interest in phenotypic drug discovery approaches. This trend has clearly been amplified by the emergence of multiple cell based assay technologies enabling a higher degree of translatability between in vitro conditions and physio pathological situations, including induced pluripotent stem cells, three dimensional models, co culture and organ on a chip systems, complemented by advances in gene editing technologies. Progress in High Content Screening technology has also contributed to the recent excitement for phenotypic drug discovery approaches, bringing image capture and processing, and data analysis, to a level of content and throughput fully compatible with large scale drug discovery efforts. Nevertheless, implementation of HCS in discovery projects must be carefully considered, to ensure optimal performance and the generation of relevant data to enable the discovery of first in class medicines.
Current opinion in pharmacology